NASDAQ · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · LARGE CAP
Icon PLC ICLR
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$8.3B
▲ 0.8% vs FY2024
EPS · FY25
$2.90
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
2.5%
Net margin · FY25
2.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 8.3B
Revenue, FY2025 · full 18-year series below
Revenue
Net income
3 cents of every revenue dollar became profit this year.
Per share
USD 2.90
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
2.5%
Return on equity, FY2025
ROE
Operating margin5.4%
Net margin2.8%
Return on assets1.4%
Each USD of equity produced 2 cents of profit this year.
Returned to shareholders
USD 740.3M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 740.3M
Share of profit322.8%
Consecutive raises—
USD 740.3M in buybacks — 323% of the year's profit, so the payout drew on cash built up earlier.
Growth
+24.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+2.1%
+24.2%
+18.0%
+15.9%
Net income
−23.2%
−7.2%
−0.4%
+6.7%
EPS, diluted
−22.1%
Returned to shareholders
+126.0%
+35.5%
+5.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.08B
Shares outstanding, FY2025
Change, 5 years−3.9%
Change, 10 years−12.4%
The share count shrank 4% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 16.3B
total assets, end of FY2025
Total assetsUSD 16.3B
EquityUSD 9.2B
CashUSD 647.3M
Gross debtUSD 2.9B
Net debtUSD 2.2B
Current ratio1.10×
Net debt stands at 24% of equity.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
8.3
8.2
8.1
7.7
5.5
2.8
2.8
2.6
1.8
1.7
1.6
1.5
1.3
1.1
0.9
0.9
0.9
0.9
Operating income $B
0.4
1.0
0.9
0.8
0.4
0.4
0.4
0.4
0.3
0.3
0.3
0.2
0.1
0.1
0.0
0.1
0.1
0.1
EBITDA $B
0.8
1.5
1.5
1.4
0.7
0.5
0.5
0.4
0.4
0.4
0.3
0.2
0.2
0.1
0.1
0.1
·
·
Income tax $B
0.0
0.1
0.0
0.1
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.2
0.7
0.6
0.5
0.2
0.3
0.4
0.3
0.3
0.3
0.2
0.2
0.1
0.1
0.0
0.1
0.1
0.1
EPS, diluted $
2.90
8.90
6.70
6.13
2.25
6.15
6.79
5.89
5.13
4.65
3.97
2.73
1.65
0.92
0.37
1.44
1.57
1.30
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
2.5
7.9
6.2
6.1
3.1
19.2
25.2
25.4
26.4
30.7
28.0
18.5
12.3
7.7
3.4
14.0
18.3
17.1
Shares out B
0.08
0.08
0.08
0.08
0.08
0.05
0.05
0.05
0.05
0.05
0.05
0.06
0.06
0.06
0.06
0.06
0.06
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
52 of 52
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed